)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Corcept Therapeutics
Corcept Therapeutics (CORT) investor relations material
Corcept Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 2026 revenue was $340.5M, up 64% YoY; net income was $126.8M versus $19.7M in Q3 2025.
FY2026 revenue guidance was reiterated at $1.1B–$1.2B, with growth expected in endocrinology and oncology.
Financial highlights
Q3 revenue was $340.5M versus $207.6M; operating income was $114.7M versus $10.2M, and net income was $126.8M versus $19.7M.
Nine-month revenue was $761.5M versus $559.3M; net income was $138.0M versus $75.4M.
Cash, cash equivalents and marketable securities totaled $662.3M at September 30, 2026, up from $544.6M at June 30.
Q3 diluted EPS was $1.01 versus $0.16; nine-month diluted EPS was $1.13 versus $0.62.
Outlook and guidance
FY2026 revenue guidance remained $1.1B–$1.2B; R&D expense is expected to be approximately the same as in 2025, while SG&A is expected to be higher.
Relacorilant’s Cushing’s syndrome NDA has a December 17, 2026 FDA target date; a European Commission decision on the ovarian cancer application is expected by year-end.
BELLA Parts B and C, TRIDENT and SYNERGY data are expected in 2027; a Phase 3 ALS trial is planned to begin in 2027.
Existing Cushing’s syndrome business is expected to generate at least $2B in annual revenue by decade-end; relacorilant could drive $3B–$5B in 2030, while Lifyorli has more than $1B in annual revenue potential.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Corcept Therapeutics
- Relacorilant anchors growth across Cushing’s syndrome and oncology, supported by $662M in cash.CORT
Investor presentation - Q2 revenue up 32% to $256.1M; Lifyorli launch boosts guidance to $1.1–$1.2B for 2026.CORTQ2 2026
- Q1 revenue up 4.9% to $164.9M; net loss $31.8M; 2026 guidance raised after Lifyorli approval.CORTQ1 2026
- Proxy seeks approval for director elections, auditor, executive pay, and equity plan amendment.CORTProxy filing
- 2025 revenue rose 13% to $761.4M, with strong Cushing's demand and advancing clinical pipeline.CORTQ4 2025
- Q3 revenue up 14% to $207.6M; net income fell as expenses rose; pipeline and NDAs advancing.CORTQ3 2025
- Q3 revenue up 48% year-over-year, relacorilant NDA submission on track, guidance raised.CORTQ3 2024
- Q2 revenue up 39% to $163.8M, guidance raised, and key clinical milestones expected by year-end.CORTQ2 2024
- Q1 revenue up 7% to $157.2M; 2025 guidance held as clinical pipeline advances.CORTQ1 2025
Next Corcept Therapeutics earnings date
Q4 202624 Feb, 2027
Corcept Therapeutics
Next Corcept Therapeutics earnings date
Q4 202624 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing and commercializing therapies that modulate the effects of cortisol. The company targets endocrine disorders, cancer, and psychiatric conditions with proprietary small-molecule compounds. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ.